421P A multicenter, randomized, double-blind, placebo (PBO)-controlled, phase III trial of lenvatinib (LEN) in patients (pts) with radioiodine-refractory differentiated thyroid cancer (RR-DTC) in China

421P A multicenter, randomized, double-blind, placebo (PBO)-controlled, phase III trial of lenvatinib (LEN) in patients (pts) with radioiodine-refractory differentiated thyroid cancer (RR-DTC) in China

Saved in:
Bibliographic Details
Published in:Annals of oncology Vol. 31; p. S1407
Main Authors: Gao, M., Ge, M., Xu, Z., Ji, Q., Shi, F., Qin, J., Wang, F., Chen, G., Zhang, Y., Huang, R., Tan, J., Huang, T., Li, S., Lv, Z., Lin, Y., Guo, Z., Kubota, T., Suzuki, T., Ikezawa, H., Zheng, X.
Format: Journal Article
Language:English
Published: Elsevier Ltd 01-11-2020
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:0923-7534
1569-8041
DOI:10.1016/j.annonc.2020.10.413